EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Krystal Biotech's enterprise value is $3,006.6 Mil.
Krystal Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $333.4 Mil. Therefore, Krystal Biotech's EV-to-Revenue for today is 9.02.
The historical rank and industry rank for Krystal Biotech's EV-to-Revenue or its related term are showing as below:
KRYS'
s EV-to-Revenue Range Over the Past 10 Years
Min: 9.38 Med: 32.62 Max: 354.21
Current: 9.02
During the past 9 years, the highest EV-to-Revenue of Krystal Biotech was 354.21. The lowest was 9.38. And the median was 32.62.
KRYS's EV-to-Revenue is ranked worse than 54.63% of 994
companies
in the Biotechnology industry
Industry Median: 7.16
vs KRYS: 9.02
As of today (2025-05-24), Krystal Biotech's stock price is $125.05.
Krystal Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $11.17. Therefore, Krystal Biotech's PS Ratio for today is 11.20.
Krystal Biotech EV-to-Revenue Historical Data
The historical data trend for Krystal Biotech's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Krystal Biotech's EV-to-Revenue
For the Biotechnology subindustry, Krystal Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's EV-to-Revenue falls into.
Krystal Biotech's current Enterprise Value is $3,006.6 Mil.
Krystal Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $333.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech's share price for today is $125.05.
Krystal Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Krystal Biotech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRYS has been successfully added to your 